WebFeb 17, 2024 · OSAKA, Japan and CAMBRIDGE, Massachusetts, February 18, 2024 – Takeda (TSE:4502/NYSE:TAK) today announced the first six-month interim analysis results from … WebMay 28, 2024 · 11521 Background: Cancer testis antigen NY-ESO-1 is expressed in multiple tumor types, including 80‒90% of MRCLS [1,2]. Overall response rates (ORRs) to MRCLS treatment are low (1L, <20%; 2L, <10%) [2]. Lete-cel, an autologous T-cell therapy, targets NY-ESO-1/LAGE-1a+ tumors using a genetically modified, high-affinity T-cell receptor. High …
Final Overall Survival and Molecular Analysis in IMmotion151, a …
WebDec 12, 2024 · In this unprespecified interim analysis, we evaluated the safety and efficacy of LentiGlobin in 35 patients enrolled in Group C. Included in this analysis was the number of severe vaso-occlusive ... WebApr 30, 2024 · At the first interim analysis (data cutoff on Dec 4, 2024; median follow-up of 14·4 months [IQR 10·2-18·7] in the pembrolizumab group and 14·3 months [10·1-18·7] in … candy crush 2109 suzy
A Phase I Clinical Trial Evaluating the Safety and Dosing of
WebJun 18, 2024 · Celgene, a Bristol-Myers Squibb Company. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, … WebMar 26, 2016 · Spend one-fifth of the available 5 percent alpha at the interim analysis. The interim analysis p value must be < 0.01 to stop the trial early and claim efficacy. Spend … WebIn the ITT population, the event rates were 54.8% for the atezolizumab plus bevacizumab group and 55.3% for the sunitinib group, and the overall survivals were 36.1 months (95% CI, 31.5-42.3 months) for the atezolizumab plus bevacizumab group and 35.3 months (95% CI, 28.6-42.1 months) for the sunitinib group. candy crush 2132 suzy